BioStrand (a subsidiary of IPA)
@BioStrandBV
Followers
908
Following
2K
Media
192
Statuses
1K
The Ultimate Convenience in Multi-Omics Data Search and Analysis | ML & AI | NLP
Belgium
Joined November 2019
@BioTechX_ has officially kicked off!. Our team—Dirk Van Hyfte, Ingrid Brands, and Arnout Van Hyfte—is ready to discuss how we can help you tackle complex datasets with our innovative solutions. Stop by booth #922 to meet the team and see our live demo!. @ImmunoPrecise #Data
0
1
4
In this insightful blog by our data scientist, Sébastien Lemal, we explore AlphaFold 3’s potential and how BioStrand’s LENSᵃⁱ platform leverages these breakthroughs to accelerate biotherapeutic development. Read our blog:
0
0
2
RT @ImmunoPrecise: 2024: A Year of Transformative Progress in Biotherapeutics. This year, we harnessed the power of the LENSᵃⁱ platform pow….
0
2
0
RT @ImmunoPrecise: Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr….
0
4
0
Data integration in #antibodydiscovery doesn’t have to be complex. With LENSᵃⁱ, streamline multi-omics data at the subsequence level for faster, sharper insights. From target discovery to lead optimization, we help you make informed decisions quickly.
0
2
5
RT @ImmunoPrecise: Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its p….
0
3
0
In her latest blog, Julie Delanote, Data Scientist at BioStrand, explores how vector search and integrated AI technologies are transforming drug discovery by analyzing proteins at the sub-sequence level. Read the blog:
0
2
4
RT @ImmunoPrecise: Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Plat….
0
5
0
Our latest article explores how #insilico methods enhance #drugdevelopment by providing rapid insights, early identification of potential failures, and cost-effective streamlining. Read our blog: #BioStrandBlogs #Immunogenicity #DrugDiscovery $IPA.
blog.biostrand.ai
Transform immunogenicity screening with LENSᵃⁱ. AI-powered in silico platform for accelerated drug development.
0
1
6
RT @ImmunoPrecise: ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with e….
0
3
0
RT @ImmunoPrecise: IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenom….
0
6
0
In our latest blog post, Saskia Debergh, BioStrand computational linguist, explains why vector search is essential for finding precise information in vast data sets through advanced text analysis. Read more in our blog: $IPA #BioStrandBlogs.
blog.biostrand.ai
Elevate drug design with LENSᵃⁱ. Vector search for enhanced text analysis and discovery.
0
3
9
RT @ImmunoPrecise: BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with….
0
8
0
RT @ImmunoPrecise: IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR). BioStra….
0
7
0
RT @ImmunoPrecise: ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Tec….
0
3
0
Our latest blog presents a detailed case study on the LENSᵃⁱ™ approach to in silico epitope binning, validated against traditional wet lab techniques. Discover how this innovation enhances scalability and accuracy in therapeutic mAb development. $IPA.
blog.biostrand.ai
In this study, we present an in silico epitope binning framework that provides highly scalable and accurate epitope analysis with in vitro-level precision.
0
3
8
RT @ImmunoPrecise: Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdis….
0
6
0
Explore our latest article to see how this technique improves data retrieval across diverse #unstructureddata types. Learn about its applications in #drugdiscovery and #healthcare, and why it's crucial for modern data-driven solutions. Read now: $IPA.
biostrand.ai
Master vector search for AI-driven drug discovery. Learn about its power, applications, and integration with LLM, RAG, and NLP.
0
2
6
Edward steps into the role of Director of Sales Europe, bringing over two decades of experience in pharma and biotech. He will be focusing on guiding both BioStrand and IPA through exciting new research collaborations across Europe. Read his interview:
blog.biostrand.ai
Meet Edward Verwayen. Learn about his journey, insights into the industry, and passion for driving innovation in antibody discovery.
0
2
10
Our latest blog provides a quick overview of epitope-driven antibody discovery, from defining epitopes to employing high-throughput in silico epitope binning techniques. Read our blog now. #BioStrandBlogs.
blog.biostrand.ai
From defining an epitope to high-throughput in silico epitope binning, and everything in between, a quick overview of epitope-driven antibody discovery.
0
1
5
Looking to grow with a talented team?. We are on the hunt for innovative minds to join us. Currently, we are looking for:. - Software Engineer Golang.- AWS Technical Architect. Think you're a fit? Apply now!
0
2
3